hematologic malignancies
Tempus, IFLI Partner to Accelerate Development of Follicular Lymphoma Therapies
The collaboration will involve making a real-world multimodal dataset available in Tempus' Lens platform that researchers can use to accelerate treatment development.
Galapagos Inks Deal With Catalent to Use New Jersey Site for Decentralized Cell Therapy Trials
The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.
NeoGenomics, Adaptive Biotech Partner to Offer Combined Blood Cancer Testing
Doctors ordering NeoGenomics Compass test packages will have the option of including Adaptive's ClonoSeq minimal residual disease assay.
Israeli Oncologists Show Point-of-Care CAR T Cells Have Comparable Efficacy to Yescarta, Kymriah
Premium
Lymphoma patients better tolerated the CAR T-cell therapy manufactured on-site at the Sheba Medical Center than they did the commercially available options.
'Fresh-In, Fresh-Out' Dual-Targeted CAR T-Cell Therapy Shows Promise in Phase II DLBCL Trial
Premium
The non-cryopreserved CD19- and CD20-directed CAR T-cell therapy zamto-cel is manufactured in a closed-system device that could enable point-of-care treatment.